New Delhi: Bharat Biotech-developed vaccine candidate COVAXIN will be affective on mutant strains of the novel coronavirus, the company expressed confidence at a press conference on Monday.
According to Bharat Biotech chairman and managing director, Dr Krishna Ella, the company will be able to establish the “hypothesis” of the candidate’s ability to protect against mutations in a week.
“It’s only a hypothesis right now…but just give me one week’s time (and) I’ll give confirmatory data,” Dr Ella was quoted as saying by The Indian Express.
He was responding to a query on whether there were data to show Covaxin is effective against the mutant strain of the SARS-CoV-2 virus. The second strain was first detected in the United Kingdom and has since been found in over 30 other countries.
ALSO READ: Covaxin 200% Safe, Says Bharat Biotech MD After Backlash On Vaccine Efficacy
